Gay, bisexual men, trans women of color sought for new DC PrEP study
The Washington Health Institute, a D.C.-based health care provider and research organization, is inviting people of color who identify as cisgender men, including gay and bisexual men, transgender women and gender nonbinary individuals to participate in a clinical trial for a new injectable HIV prevention medication that needs to be taken only once every six months.
A statement released by the Washington Health Institute says the study will assess the effectiveness of the drug lenacapavir, which has been approved by the U.S.
Food and Drug Administration for use as an effective treatment for people with HIV, as a form of PrEP to prevent HIV infection.
Those participating in the study will receive a payment of $100 each time they visit the Washington Health Institute’s facility at 1140 Varnum St., N.E., to be interviewed and undergo medical tests, according to the statement.
